Valuation: Absci Corporation

Market Cap 1.41B 1.23B 1.13B 1.04B 1.97B 135B 2.01B 13.54B 5.33B 66.27B 5.28B 5.16B 228B P/E 2026 *
-10.6x
P/E 2027 * -12.5x
Enterprise Value 1.27B 1.11B 1.03B 945M 1.78B 122B 1.82B 12.25B 4.82B 59.96B 4.77B 4.67B 206B EV / Sales 2026 *
224x
EV / Sales 2027 * 70.8x
Free-Float
87.96%
Yield 2026 *
-
Yield 2027 * -
1 day+0.79%
1 week-21.75%
Current month-28.43%
1 month+11.94%
3 months+131.70%
6 months+174.67%
Current year+137.68%
1 week 7.58
Extreme 7.58
10.5
1 month 7.37
Extreme 7.37
12.06
Current year 2.24
Extreme 2.24
12.06
1 year 2.24
Extreme 2.24
12.06
3 years 1.11
Extreme 1.1111
12.06
5 years 1.11
Extreme 1.1111
31.53
10 years 1.11
Extreme 1.1111
31.53
Manager TitleAgeSince
Chief Executive Officer 36 2011-07-31
Director of Finance/CFO 53 2023-08-30
Chief Tech/Sci/R&D Officer - 2025-07-31
Director TitleAgeSince
Director/Board Member 36 2010-12-31
Director/Board Member 59 2020-07-31
Director/Board Member 57 2022-01-06
Date Insider Type Main position Quantity % Market Cap.
6/30/26 Buy

Director

12,900 0.0076%
6/24/26 Tax

Founder

-59,896 0.0384%
6/4/26 Free

Director

41,600 0.0267%
Change 5-day change 1-year change 3-year change Capi.($)
+0.79%-21.75%+165.87%+245.62% 1.41B
-0.37%-3.70%+0.93%+2.61% 49.18B
+3.90%-0.39%+386.06%+588.97% 39.58B
-1.70%+4.46%+5.93%+61.54% 34.69B
-2.01%-0.76%+28.41%-8.52% 34.42B
+0.06%+0.34%+2.38%+34.47% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+116.45% 15.36B
+0.37%+1.50%+14.55%+17.33% 14.05B
0.00%+1.36%+18.43%-31.23% 13.02B
Average +0.14%-2.15%+77.22%+114.14% 24.5B
Weighted average by Cap. +0.09%-0.30%+80.25%+123.17%

Financials

2026 *2027 *
Net sales 5.67M 4.96M 4.57M 4.22M 7.95M 546M 8.12M 54.66M 21.5M 267M 21.3M 20.83M 921M 17.68M 15.45M 14.25M 13.14M 24.76M 1.7B 25.31M 170M 67.01M 834M 66.38M 64.92M 2.87B
Net income -125M -109M -101M -92.93M -175M -12.04B -179M -1.21B -474M -5.9B -470M -459M -20.3B -121M -106M -97.68M -90.03M -170M -11.66B -173M -1.17B -459M -5.71B -455M -445M -19.67B
Net Debt -134M -117M -108M -99.54M -188M -12.9B -192M -1.29B -508M -6.32B -503M -492M -21.74B -154M -135M -124M -114M -216M -14.83B -221M -1.48B -584M -7.26B -578M -566M -25.01B
Logo Absci Corporation
Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Employees
140
Date Price Change Volume
26-07-17 US$8.295 +0.79% 3,719,042
26-07-16 US$8.230 -15.68% 7,431,764
26-07-15 US$9.760 -4.59% 3,438,583
26-07-14 US$10.23 +0.20% 3,287,544
26-07-13 US$10.21 -3.68% 2,925,498
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.295USD
Average target price
13.78USD
Spread / Average Target
+66.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABSI Stock